NEW YORK CITY, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO.
Investigation Details
On March 27, 2025, Bausch & Lomb announced a voluntary recall of intraocular lenses on its enVista platform due to reports of toxic anterior segment syndrome (TASS), a potential complication in cataract surgery. The recall may raise short-term concerns about product safety and regulatory scrutiny. Following this news, Bausch & Lomb's stock price dropped $1.50 per share, or 10.6%, to close at $15.00 that same day.
What's Next?
If you are aware of any facts relating to this investigation or purchased Bausch & Lomb securities, you can assist this investigation by visiting the firm's site: bgandg.com/BLCO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original
press release on ACCESS Newswire
